-- 根據週四提交給澳洲證券交易所的文件顯示，PYC Therapeutics（ASX：PYC）已啟動一項針對多囊腎患者的1b期多次遞增劑量研究，並完成了首例患者使用其候選藥物PYC-003的給藥。 該研究旨在確定PYC-003的安全性/耐受性以及最佳重複給藥方案，之後計劃過渡到註冊性2/3期聯合試驗。 根據文件，研究還將測量其他終點指標，包括尿液PC1蛋白水平、磁振造影顯示的腎臟總體積以及估計的腎小球濾過率。 該公司股價在周四的交易中上漲了近5%。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661